Synta Announces Upcoming Presentations at the 15th World Conference on Lung Cancer

  Synta Announces Upcoming Presentations at the 15th World Conference on Lung
  Cancer

   Webcast and conference call scheduled for 8 AM ET on Monday, October 28

Business Wire

LEXINGTON, Mass. -- October 23, 2013

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results from
the GALAXY-1 trial, which evaluates the Company’s lead drug candidate
ganetespib in patients with advanced non-small cell lung adenocarcinoma, will
be presented during an oral session at the 15^th World Conference on Lung
Cancer (WCLC) in Sydney, Australia:

“Randomized Phase II study of docetaxel with or without ganetespib in advanced
lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma
patients”

Abstract #: O03.01
Session: Oral Abstract Session, NSCLC – Targeted Therapies I
Date and time: Monday, October 28. 10:30 AM – 12:00 PM local time
Location: Bayside Auditorium B, Level 1
Presenter: Suresh Ramalingam, M.D., Winship Cancer Institute, Emory
University, Atlanta, GA

Results will be presented from the analysis planned for one year from the last
patient enrolled in the 253-patient primary enrollment phase of GALAXY-1. The
Company expects to release these results on Saturday, October 26, 2013,
concurrent with the beginning of the WCLC meeting.

Based upon the number of overall survival events, Synta expects that the final
overall survival analysis of GALAXY-1 will be conducted by early 2014.

Other presentations

Additional ganetespib presentations at the WCLC include:

“Antimetastatic activity of ganetespib: preclinical studies and assessment of
new lesion growth in the GALAXY-1 NSCLC trial”

Abstract #: P1.01-007
Session: Poster Session 1 – Cancer Biology
Date and Time: Monday, October 28. 9:30 AM – 4:30 PM local time
Location: Exhibit Hall, Ground Level
Presenter: Vojo Vukovic, M.D., Ph.D., Synta Pharmaceuticals, Lexington, MA

“Novel mechanisms of sensitivity and acquired resistance to Hsp90 inhibition
by ganetespib”

Abstract #: MO12.01
Session: Prognostic and Predictive Biomarkers III
Date and Time: Tuesday, October 29. 10:30 AM – 12:00 PM local time
Location: Parkside Ballroom B, Level 1
Presenter: Sara Busacca, Ph.D., University of Leicester, Leicester, UK

Conference call

Synta will host a webcast and conference call at 8:00 AM ET on Monday, October
28, 2013, to discuss these results.

The webcast, which will include both audio and slides, can be accessed by
visiting the home page or the Investor Relations section of the Synta
Pharmaceuticals website, www.syntapharma.com.

The conference call can be accessed by dialing (877) 407-8035 (U.S.) or (201)
689-8035 (International). Participants can follow along with a prepared slide
presentation that will be available on the home page of the company’s website,
www.syntapharma.com. For those unable to join the live call, a replay will be
available from 12:00 PM ET on October 28 through 11:59 PM ET on November 4. To
access the replay, please dial (877) 660-6853 (U.S.) or (201) 612-7415
(International) and refer to conference ID 10000731.

About Ganetespib

Ganetespib, an investigational drug candidate, is a selective inhibitor of
heat shock protein 90 (Hsp90), a molecular chaperone which controls the
folding and activation of a number of client proteins that drive tumor
development and progression. Many solid and hematologic tumors are dependent
on Hsp90 client proteins including proteins involved in “oncogene addiction”
(ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2);
proteins involved in resistance to chemotherapy and radiation therapy (ATR,
BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in
angiogenesis (HIF-1alpha, VEGFR, PDFGR, and VEGF); and proteins involved in
metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical
models, inhibition of Hsp90 by ganetespib results in the inactivation,
destabilization, and eventual degradation of these cancer-promoting proteins.
Ganetespib is being evaluated in trials in lung cancer, breast cancer, and
other tumor types. The most common adverse event seen to date has been
transient, mild or moderate diarrhea, which has been manageable with standard
supportive care. Information on these trials can be found at
www.clinicaltrials.gov. Ganetespib has received Fast Track designation from
FDA for second-line treatment of non-small cell lung adenocarcinoma in
combination with docetaxel.

About the GALAXY Program

The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) program
consists of two randomized trials comparing the combination of ganetespib and
docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have
received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1)
to determine the patient population most likely to derive benefit from
ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2). More
information about the GALAXY trials can be found at www.clinicaltrials.gov
(NCT01348126 and NCT01798485).

About Lung Cancer

Lung cancer is the leading cause of cancer-related death in the world,
accounting for nearly 1.4 million deaths in 2008, according to the World
Health Organization. The five-year survival rate for this disease is
approximately 16%; over half of people with lung cancer die within one year of
being diagnosed. In the U.S., the American Cancer Society estimates that
228,000 cases of lung cancer will be diagnosed in 2013. Non-small cell
adenocarcinoma comprises about 40% of all lung cancer.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities. For more
information, please visit www.syntapharma.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified by the
use of forward-looking terminology such as "will", "would", "should",
"expects", "anticipates", "intends", "plans", "believes", "may", "estimates",
"predicts", "projects", or similar expressions intended to identify
forward-looking statements. Such statements, including statements relating to
the timing of the final overall survival analysis from the GALAXY-1 trial,
reflect our current views with respect to future events and are based on
assumptions and subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements, including those described in "Risk Factors" of our
Form 10-K for the year ended December 31, 2012 as filed with the Securities
and Exchange Commission. Synta undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future events
or otherwise, except as required by law.

Contact:

Investor Relations Contact:
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
gfarmer@syntapharma.com
or
Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com
or
Media Contact:
Argot Partners
Eliza Schleifstein, 973-361-1546
eliza@argotpartners.com
 
Press spacebar to pause and continue. Press esc to stop.